Nurix Therapeutics Bexdeg’s EHA Update Showcases Durable Responses & High Earlier-Line ORR

Research evidence excerpt

Nurix Therapeutics Bexdeg’s EHA Update Showcases Durable Responses & High Earlier-Line ORR

J P M O R G A N North America Equity Research

11 June 2026

Nurix Therapeutics Overweight

NRIX, NRIX US

Bexdeg’s EHA Update Showcases Durable Responses Price (10 Jun 26):$15.30

& High Earlier-Line ORR

SMid Biotechnology

Tessa T Romero AC

(1-212) 622-4484

tessa.t.romero@jpmchase.com

Caroline Pocher

(1-212) 622-8204

caroline.pocher@jpmchase.com

This morning, Nurix announced updated results from their ongoing phase 1a/b study

Mariam Waggeh

evaluating bexobrutideg (bexdeg) in chronic lymphocytic leukemia (CLL), which

(1-212) 622-1711

will be presented during an oral presentation at the 2026 EHA Congress (June 11-14th; mariam.waggeh@jpmchase.com

Stokholm, Sweden), and we wanted to provide our key takeaways. Overall, in J.P. Morgan Securities LLC

addition to supporting an overall safe profile observed across the phase 1a/b CLL

cohorts (n=142), we view the updates (see below for more details; data cut-off as of

Jan 1st, 2026) from the phase 1a dose escalation study (n=48) showcasing consistent *Roche is covered by J.P. Morgan

efficacy and safety that is supportive of bexdeg’s durability in a heavily pretreated Securities plc European Pharmaceuticals

population (see our note here; data cut-off from ASH 2025: Sept. 19, 2025); we were & Biotechnology analyst, Richard Vosser.

particularly encouraged to see new data from the phase 1b earlier treatment cohorts,

specifically Cohort 5 (BTKi treated / BCL2 naive) and Cohort 15 (BTKi naïve,

including treatment naive), which showed high response rates even in an earlier-line

population. Looking ahead, the pivotal, single-arm, phase 2 DAYBreak CLL-201

study remains ongoing and is evaluating 600mg bexdeg in the 3L+ setting (post-